Medical professionals in New Zealand remain cautious regarding the clinical use of psilocybin, despite the substance being legal for private patient prescriptions for one year. While research trials from institutions like Imperial College London indicate potential benefits for treating depression and addiction, only two doctors in New Zealand currently hold Medsafe approval to prescribe the treatment, and just 10 patients have been treated to date.
Why are medical practitioners cautious about psilocybin?
Many health professionals cite concerns regarding the safety and potential for harm associated with psychedelic substances. Dr. James Simonsson, a health worker who recently completed a six-day training course at the Psychedelic Training Centre, described himself as “curious but cautious” about the practice. According to Simonsson, his hesitation stems from witnessing cases of complex psychosis linked to the recreational use of psilocybin.
Professor Suresh Muthukumaraswamy, a psychopharmacology expert based in New Zealand, noted that the medical community’s slow adoption is appropriate given the relative novelty of the evidence. He cautioned against “jump on the latest bandwagon.”
While psilocybin is a Class A drug in New Zealand, it has been legal for use in Australia through medical prescriptions since 2023.
How does psilocybin therapy function in a clinical setting?
Research suggests that psilocybin interacts with the brain differently than traditional Selective Serotonin Reuptake Inhibitors (SSRIs). Professor David Nutt of Imperial College London explains that psilocybin works on the cortex, potentially disrupting the repetitive, negative thought patterns often present in patients suffering from depression, OCD, anorexia, or addiction.
According to Nutt, the substance may assist with neuroplasticity, allowing patients to break free from cycles of worthlessness or guilt. However, medical guidelines emphasize that psilocybin should not be administered to individuals with a personal or family history of psychosis.
What are the barriers to wider access?
Financial and regulatory hurdles currently limit the availability of psilocybin therapy in New Zealand. Because Medsafe has not yet approved or publicly funded any psilocybin products, patients must cover the entire cost of treatment themselves. Treatment typically requires a 25mg dose and costs at least $9000.
Associate Health Minister David Seymour suggested that the low uptake might be influenced by “prejudices in the past” regarding psychedelics. Seymour indicated that as more data becomes available from private providers, the government may evaluate whether the treatment could eventually be considered a “good deal for the taxpayer.”
Cultural and ethical considerations
The potential commercialization of psilocybin raises ethical questions. Dr. Simonsson noted that because psychedelic mushrooms are endemic to Aotearoa, the medicine should be introduced with “sovereignty and care” rather than a primary focus on monetization. He expressed a desire to ensure the treatment is not used haphazardly.
Frequently Asked Questions
- Is psilocybin legal in New Zealand? It is legal for medicinal use, but only for patients who receive a prescription from a Medsafe-approved doctor. It remains a Class A drug otherwise.
- Who is eligible for psilocybin treatment? While clinical trials focus on depression and addiction, individuals with a family or personal history of psychosis are advised against its use.
- Why is the treatment so expensive? Currently, there is no public funding for psilocybin in New Zealand, meaning patients must pay the full market price for private clinical care.
Are you interested in the intersection of mental health policy and emerging medical research? Subscribe to our newsletter for the latest updates on healthcare innovation in New Zealand.
